GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Future Policy Benefits

Cabio Biotech (Wuhan) Co (SHSE:688089) Future Policy Benefits


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Cabio Biotech (Wuhan) Co Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Xiao Min senior management
Shang Yun Core technical personnel
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director